Please login to the form below

Not currently logged in
Email:
Password:

Aeras

This page shows the latest Aeras news and features for those working in and with pharma, biotech and healthcare.

Tuberculosis: treatment and prevention

Tuberculosis: treatment and prevention

Aeras and GlaxoSmithKline (GSK) Biologicals have entered into a public-private partnership to develop GSK's tuberculosis vaccine candidate, GSK 692342. ... incentives. The Bill and Melinda Gates Foundation recently gifted $280m to the Aeras Global TB

Latest news

  • GSK boost vaccines capabilities with €250m Okairos purchase GSK boost vaccines capabilities with €250m Okairos purchase

    Okairos, which has received investment from BioMedInvest, Boehringer Ingelheim, LSP, Novartis and Versant Ventures, has already received attention for its novel chimpanzee-based platform, including a collaboration with Aeras and the

  • TB vaccine disappoints, but others in the pipeline TB vaccine disappoints, but others in the pipeline

    Helen McShane of the University of Oxford in the UK. The trial was sponsored by non-profit vaccines company Aeras, the Wellcome Trust and the Oxford-Emergent Tuberculosis Consortium (OETC), a ... Meanwhile, there are several other TB vaccines in the

  • Dutch invest in TB vaccines

    The funding has also made a valuable contribution to Crucell and Aeras' AdVac-based TB vaccine. ... of limited investment - which Aeras TB Global president and CEO, Dr Jerald Sadoff, hopes will be further remedied by the recent Dutch input.

  • Tackling the TB threat

    Among these is a recombinant adenoviral vector TB vaccine, currently in phase I trials, being developed by Crucell and Aeras Global TB Vaccine Foundation, an international non-profit academia-industry partnership. ... Further along the pipeline, in phase

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Interview: Charles Mgone, EDCTP Interview: Charles Mgone, EDCTP

    But it doesn't stop the contagious form acquired by adults. So we are working with Emergent BioSolutions and Aeras, a non-profit product developer, as well as institutions in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics